EUVIMEDSkopri EUVIMED
Crossref

Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA

Cristina Rubín de Célix iD, Elena Ricart, M Dolores Martín-Arranz, Ruth de Francisco, Francisco Javier García-Alonso, Francisco Mesonero iD, Fernando Gomollón, Luisa de Castro, Laura Ramos, Santiago García-López, Lara Arias, Miriam Mañosa iD and 48 more

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70312 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Cristina Rubín de Célix and 59 co-authors. Institution: Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain. Major MEDLINE topics: Inflammatory Bowel Diseases, Biological Products, Gastrointestinal Agents, Biological Therapy. Cited 7 times so far (Crossref); 41 references. Funded by: Eli Lilly and Company.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Real‐world data on dose escalation/de‐escalation in inflammatory bowel disease (IBD) are scarce.

Aims

To assess the frequency, effectiveness and durability of escalation/de‐escalation of infliximab, adalimumab, golimumab, vedolizumab and ustekinumab in IBD, and to identify factors influencing relapse and drug discontinuation and re‐escalation efficacy.

Methods

We included patients from the ENEIDA registry of GETECCU who were exposed to biologics and analysed escalations/de‐escalations. We assessed the impact of variables on durability, drug discontinuation and relapse after escalation/de‐escalation.

Results

Of 19,720 patients on biologics, 5096 (26%) underwent dose escalation. Frequency of escalation per patient‐year was 5% (infliximab), 7% (adalimumab), 7% (golimumab), 10% (vedolizumab) and 12% (ustekinumab). Clinical remission was recaptured in 32%–49% of patients. Durability of escalation (24 months) ranged from 66% to 88%. Drug discontinuation was associated with previous biologic exposure and disease duration (infliximab), monotherapy (adalimumab) and ulcerative colitis (ustekinumab). There were 669 de‐escalations. The frequency per patient‐year was 6%, 9%, 5%, 6% and 3% for infliximab, adalimumab, golimumab, vedolizumab and ustekinumab. Maintenance of remission after de‐escalation was observed in 75%–100%. Durability of de‐escalation (12 months) was 82%–90%. Factors associated with relapse were biologic exposure (infliximab) and age at de‐escalation (adalimumab). Re‐escalation benefited most patients.

Conclusions

In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De‐escalation is feasible in some patients. Re‐escalation is generally effective after relapse.

Subjects

MeSH terms (MEDLINE)

Inflammatory Bowel DiseasesBiological ProductsGastrointestinal AgentsBiological TherapyAntibodies, MonoclonalHumansFemaleMaleAdultMiddle AgedTreatment OutcomeDose-Response Relationship, DrugRegistriesInfliximabAdalimumabAntibodies, Monoclonal, HumanizedRecurrenceAged

Author keywords

biologicsdose escalationinflammatory bowel disease

Substances

Biological ProductsGastrointestinal AgentsInfliximabAdalimumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonalgolimumab

Authors and institutions

  • Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Department of Gastroenterology, Hospital Clínic i Provincial, Institut D'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and CIBEREHD, Barcelona, Spain.
  • Department of Gastroenterology, Hospital Universitario de La Paz, Madrid, Spain.
  • Department of Gastroenterology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
  • Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain.
  • Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

ORCID profiles: Cristina Rubín de Célix, Francisco Mesonero, Miriam Mañosa, Xavier Calvet, María José Casanova, Iago Rodríguez-Lago, Carlos Taxonera, Ana Gutiérrez, Alfredo J Lucendo

Funding

  • Eli Lilly and Company

Cite

APA

Rubín de Célix, C., Ricart, E., Martín-Arranz, M. D., de Francisco, R., García-Alonso, F. J., Mesonero, F., Gomollón, F., de Castro, L., Ramos, L., García-López, S., Arias, L., Mañosa, M., Iglesias, E., Calvet, X., Suria Bolufer, C., Casanova, M. J., Pérez-Calle, J. L., Giordano, A., Sierra-Ausín, M., …, & Argüelles-Arias, F. (2026). Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70312

Vancouver

Rubín de Célix C, Ricart E, Martín-Arranz MD, de Francisco R, García-Alonso FJ, Mesonero F, et al. Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70312

BibTeX
@article{RubndeClix2026,
  author = {Rubín de Célix, Cristina and Ricart, Elena and Martín-Arranz, M Dolores and de Francisco, Ruth and García-Alonso, Francisco Javier and Mesonero, Francisco and Gomollón, Fernando and de Castro, Luisa and Ramos, Laura and García-López, Santiago and Arias, Lara and Mañosa, Miriam and Iglesias, Eva and Calvet, Xavier and Suria Bolufer, Carles and Casanova, María José and Pérez-Calle, José Lázaro and Giordano, Antonio and Sierra-Ausín, Mónica and Vera, Isabel and Navarro-Llavat, Mercè and Lorente, Rufo and Piqueras, Marta and Rivero, Montserrat and Guardiola, Jordi and Esteve, María and Fuentes Coronel, Ana and Rodríguez-Lago, Iago and Ponferrada-Díaz, Ángel and Ber, Yolanda and Tardillo, Carlos and Márquez, Lucía and Carpio, Daniel and Taxonera, Carlos and Bermejo, Fernando and Busquets, David and Camps, Blau and Gutiérrez, Ana and García-Sepulcre, Mariana Fe and Barreiro-de Acosta, Manuel and Marín-Jiménez, Ignacio and Huguet, José M and Fernández-Salazar, Luis Ignacio and Jaó, Jordina and Rodríguez-Gutiérrez, Cristina and Martínez-Flores, Carlos and Bujanda, Luis and Lucendo, Alfredo J and Sesé, Eva and Robledo Andrés, Pilar and Ginard, Daniel and Vega, Pablo and Riera, Joan and Pajares, Ramón and Van Domselaar, Manuel and Almela, Pedro and Martínez Pérez, Teresa and Muñoz-Villafranca, Carmen and Varela, Pilar and Argüelles-Arias, Federico},
  title = {Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70312}
}
Start for free →